This page lists the SEC filings reported by Ridgeback Capital Investments L.P..
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-14 | Ridgeback Capital Investments L.P. | Affimed N.V. | 14,858,982 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-14 | Ridgeback Capital Investments L.P. | BICYCLE THERAPEUTICS plc | 844,235 | 2.2% | EDGAR |
| SC 13G | 2024-01-26 | Ridgeback Capital Investments L.P. | Pyxis Oncology, Inc. | 4,345,228 | 9.8% | EDGAR |
| SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | BICYCLE THERAPEUTICS plc | 2,264,801 | 7.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | Affimed N.V. | 12,882,610 | 8.8% | EDGAR |
| SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 52,509 | 0.2% | EDGAR |
| SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | BICYCLE THERAPEUTICS plc | 2,264,801 | 7.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | Affimed N.V. | 12,882,610 | 8.8% | EDGAR |
| SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 52,509 | 0.2% | EDGAR |
| SC 13G/A | 2022-02-14 | Ridgeback Capital Investments L.P. | Affimed N.V. | 7,722,106 | 6.5% | EDGAR |
| SC 13G/A | 2022-02-14 | Ridgeback Capital Investments L.P. | BICYCLE THERAPEUTICS plc | 2,164,801 | 7.4% | EDGAR |
| SC 13G/A | 2022-02-14 | Ridgeback Capital Investments L.P. | Cogent Biosciences, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 1,834,360 | 8.9% | EDGAR |
| SC 13G | 2021-04-14 | Ridgeback Capital Investments L.P. | Affimed N.V. | 6,450,000 | 5.5% | EDGAR |
| SC 13G/A | 2021-04-09 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 494,360 | 5.4% | EDGAR |
| SC 13G/A | 2021-02-16 | Ridgeback Capital Investments L.P. | BICYCLE THERAPEUTICS plc | 1,861,833 | 8.7% | EDGAR |
| SC 13G/A | 2021-02-16 | Ridgeback Capital Investments L.P. | 4D Molecular Therapeutics Inc. | 1,100,000 | 4.2% | EDGAR |
| SC 13G/A | 2021-02-16 | Ridgeback Capital Investments L.P. | Cogent Biosciences, Inc. | 1,252,250 | 5.2% | EDGAR |
| SC 13G/A | 2021-02-16 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 407,567 | 4.5% | EDGAR |
| SC 13G/A | 2021-02-16 | Ridgeback Capital Investments L.P. | MYOMO, INC. | 104,755 | 2.3% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.